President John Dramani Mahama’s commitment to transforming Ghana’s healthcare sector is gaining momentum with the launch of the Mahama Cares Fund and the latest announcement of a partnership with global pharmaceutical giant Pfizer Inc.
This strategic initiative is central to Ghana’s renewed national effort to tackle non-communicable diseases, ensure universal access to life-saving medicines, and strengthen the overall healthcare delivery system.
The Mahama Cares Fund, established by President Mahama, is the financial backbone of the Mahama Cares Programme – an initiative designed to address critical national health priorities with a specific focus on non-communicable diseases such as cancer, diabetes, and cardiovascular conditions.
According to Joyce Bawah Mogtari, the President’s Special Aide, the Fund is driven by a promise to improve health outcomes by ensuring that funding is far-reaching.
“President John Dramani Mahama promised to improve health care – and to ensure that funds are available to support those who need it most. The Mahama Cares Fund was established – to help shape Ghana’s healthcare delivery”
Joyce Bawah Mogtari, President’s Special Aide
The Mahama Cares initiative offers what Mogtari described as “two major opportunities.” Aside from providing affordable access to life-saving medicines and vaccines, it supports an enhanced healthcare delivery system through “focused funding and targeted research.”
She emphasized that these dual pillars are “vital for advancing equitable and affordable healthcare across the country.”
A significant development under this initiative is the entry of Pfizer Inc., which has announced plans to invest directly in the Mahama Cares Fund. The pharmaceutical firm will be providing its complete portfolio of patented specialist medicines and vaccines to 45 lower-income countries, including Ghana, strictly on a not-for-profit basis.
This means that Ghanaians battling cancer and other chronic illnesses will gain access to essential drugs at a reduced cost – estimated to be approximately 70% lower than prevailing market prices.
This landmark decision by Pfizer is expected to ease the immense pressure on Ghana’s national health system and further accelerate the goals of the Mahama Cares Programme.
According to the Office of the President, this move marks one of the most significant public-private partnerships in the health sector in recent years and has the potential to redefine affordability in health care.
Bilateral and Strategic Dialogue
Mogtari credited Dr. Valerie Sawyerr, a key strategist and former presidential aide, and President Mahama himself for facilitating the initial engagements that led to Pfizer’s commitment. She also highlighted her direct involvement in building the relationship with Pfizer’s leadership.
“I was pleased to engage with the Pfizer team, including Ali Besri, Ismahene Ben Mehidi, Pauline Irungu, and Philip Selasie Tagboto. We explored how Ghana can fully harness the potential of this partnership to deliver lasting impact for our citizens”
Joyce Bawah Mogtari, President’s Special Aide
The focus of the discussions, she said, was on ensuring that this collaboration goes beyond the supply of affordable medications to include sustained investment in healthcare infrastructure, data systems, and patient-centered innovations that are responsive to Ghana’s unique healthcare challenges.
Health analysts say the Mahama Cares Fund and Pfizer’s involvement could prove to be a turning point in Ghana’s approach to non-communicable diseases, which continue to place a growing burden on public hospitals and rural clinics alike.
For citizens who previously could not afford treatment, the availability of subsidized medication could mean the difference between life and death.
Beyond patient care, the initiative is likely to influence health financing strategies across sub-Saharan Africa, setting a new precedent for how governments can collaborate with pharmaceutical giants to deliver on social health mandates.
With Ghana as one of the flagship countries under this plan, President Mahama’s government is positioning itself as a leader in global health innovation with tangible outcomes.
READ MORE: SML Decries OSP’s Raid as “Unjustified and Disruptive,” Warns of Revenue Risks
